LOW-DOSE CYCLOSPORINE AND MYCOPHENOLATE MOFETIL IN RENAL ALLOGRAFT RECIPIENTS WITH SUBOPTIMAL RENAL FUNCTION1,2

Abstract

These short-term results show that MMF introduction allows a CsA dose reduction, which improves renal function, reduces TGF-beta1 production, and improves the control of hypertension, without increasing the incidence of acute rejection.